Users' Guides to the Medical Literature
Guyatt G, Rennie D, Meade MO, Cook DJ
Part B Therapy
Chapter 10.4. Composite Endpoints
Gordon Guyatt, Victor Montori, Ignacio Ferreira-González, Jason W. Busse, Holger Schünemann, Roman Jaeschke, Gaietà Permanyer-Miralda
The Irbesartan Diabetic Nephropathy Trial7 randomized 1715 hypertensive patients with...
Topics Discussed:
aspirin, atherosclerosis, clopidogrel, composite endpoints, confidence interval, diabetic nephropathy, health outcomes, hypertension, relative risk reduction
Excerpt:
"Comfort with using a CEP as the basis of clinical decision
making rests in part on confidence that similar RRRs apply
to the more and the less important components. Investigators should
therefore construct CEPs in which the biology would lead
us to expect similar effects across components...."
Log in to read the full chapter:
Get full access to JAMAevidence two ways:
Subscribe to JAMAevidence
JAMAevidence is a subscription-
based website dedicated to the learning, teaching, and practicing of evidence-based medicine.
Pay Per View
Timed access to all of JAMAevidence
24 hours for $29.95
48 hours for $49.95